U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528716) titled 'Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy' on March 29.
Brief Summary: Based on total pathologic complete response (tpCR) after surgery, to evaluate the efficacy of an artificial intelligence model-matched anti-HER2 targeted treatment strategy (investigational arm) versus nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm) as neoadjuvant therapy for patients with early or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: SHR- A1811...